Gene Mapping Reveals Mutation in Myeloma Patients Linked to High Risk of Treatment Failure
By LabMedica International staff writers Posted on 04 May 2015 |
Image: Representation of a member of the APOBEC family of deaminase enzymes (Photo courtesy of Wikimedia Commons).
Gene mapping of patients suffering from myeloma has enabled the identification of a genetic signature linked to the likelihood of the disease becoming more genetically complex and more likely to evolve into treatment-resistant forms.
Investigators at the Institute of Cancer Research (London, United Kingdom) sequenced 463 presenting cases of myeloma enrolled in the United Kingdom Myeloma XI study using whole exome sequencing, which determines the DNA sequence of the protein-coding exon regions of tens of thousands of genes simultaneously.
They reported detecting an APOBEC mutational signature in 3.8% of cases. APOBEC, also known as apolipoprotein B mRNA-editing enzyme, encodes a member of the AID/APOBEC family of polynucleotide (deoxy) cytidine deaminases, which convert cytidine to uridine. Other AID/APOBEC family members are involved in mRNA editing, somatic hypermutation, recombination of immunoglobulin genes, and innate immunity to retroviral infection.
Patients with a genetic signature that included the APOBEC mutation had an increased mutational load and a poor prognosis for recovery.
Senior author Dr. Gareth Morgan, professor of hematology at the Institute of Cancer Research, said, “The treatment of myeloma has improved in recent years, but there are still a significant number of patients who succumb to the disease. Our research has identified, for the first time, several genetic features that indicate which patients are at high risk of developing more advanced cancer. In the future we hope to be able to use this information to test for patients most at risk, and be able to target specific treatment to their individual needs, bolstering their chance of survival.”
Related Links:
Institute of Cancer Research
Investigators at the Institute of Cancer Research (London, United Kingdom) sequenced 463 presenting cases of myeloma enrolled in the United Kingdom Myeloma XI study using whole exome sequencing, which determines the DNA sequence of the protein-coding exon regions of tens of thousands of genes simultaneously.
They reported detecting an APOBEC mutational signature in 3.8% of cases. APOBEC, also known as apolipoprotein B mRNA-editing enzyme, encodes a member of the AID/APOBEC family of polynucleotide (deoxy) cytidine deaminases, which convert cytidine to uridine. Other AID/APOBEC family members are involved in mRNA editing, somatic hypermutation, recombination of immunoglobulin genes, and innate immunity to retroviral infection.
Patients with a genetic signature that included the APOBEC mutation had an increased mutational load and a poor prognosis for recovery.
Senior author Dr. Gareth Morgan, professor of hematology at the Institute of Cancer Research, said, “The treatment of myeloma has improved in recent years, but there are still a significant number of patients who succumb to the disease. Our research has identified, for the first time, several genetic features that indicate which patients are at high risk of developing more advanced cancer. In the future we hope to be able to use this information to test for patients most at risk, and be able to target specific treatment to their individual needs, bolstering their chance of survival.”
Related Links:
Institute of Cancer Research
Latest Pathology News
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy